Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2000;102:2794

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strickberger, S. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Strickberger, S. A.

(Circulation. 2000;102:2794.)
© 2000 American Heart Association, Inc.


CLINICAL ABSTRACTS

Multicenter Randomized Trial Comparing Amiodarone to Implantable Defibrillator in Patients With Nonischemic Cardiomyopathy and Asymptomatic Nonsustained Ventricular Tachycardia: AMIOVIRT Trial

S. Adam Strickberger

for the AMIOVIRT Investigators.

Introduction. Patients (pts) with nonischemic dilated cardiomyopathy (NIDCM) and asymptomatic (asx) nonsustained ventricular tachycardia (NSVT) are at high risk for sudden cardiac death. Amiodarone or an implantable defibrillator (ICD) may reduce mortality in this patient group. Therefore, the purpose of this multicenter, randomized trial was to compare the total mortality rate associated with amiodarone to ICD therapy in patients with NIDCM and asx NSVT. Methods. Pts with NIDCM, left ventricular ejection fraction < 0.35, and asx NSVT were eligible for study participation. 102 pts were randomized to receive either amiodarone or ICD therapy. 75 pts were followed in a study registry. Because there were no identifiable differences in clinical characteristics between randomized and registry pts, all pts were grouped according to initial therapy, irrespective of whether they were randomized or were followed in the study registry. The pts were 59±12 yrs, 29% were women, the left ventricular ejection fraction (LVEF) was 0.22±0.08, 85% had either NYHA Class II or III heart failure, and the mean follow-up was 20.1±12.6 months. The primary study endpoint was total mortality. The study was designed to achieve 80% power to identify a reduction in total mortality from 20% to 10% (219 patients in each group). Stopping rules included a mortality difference associated with a p < 0.025, or p >= 0.05 (90% power) when the data were extrapolated to 600 patients. Results. The stopping rule for futility was reached, and the study was stopped early. The percent of patients surviving at 2 years (88% vs 89%) and 4 years (85% vs 79%) in the amiodarone and ICD treatment groups, respectively, were similar (p=0.6). Conclusions. In pts with NIDCM, LVEF <0.35, and asx NSVT the total mortality rate at 4 years is the same in pts treated with Amiodarone or an ICD.




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. H. Hohnloser, T. Klingenheben, D. Bloomfield, O. Dabbous, and R. J. Cohen
Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study
J. Am. Coll. Cardiol., June 18, 2003; 41(12): 2220 - 2224.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart J SupplHome page
C Stellbrink, A.-M Sinha, B Diem, A Auricchio, S Boccanelli, J Brugada, H Klein, J Morgan, L Padeletti, E Aliot, et al.
Implantable card ioverter-defibrillators with or without cardiac resynchronization therapy -- multiple therapy in a single device: a review with special reference to the PACIVIAN study
Eur. Heart J. Suppl., April 1, 2002; 4(suppl_D): D88 - D94.
[Abstract] [PDF]


Home page
J Am Coll CardiolHome page
W. Grimm, J.u. Hoffmann, H.-H. Muller, and B. Maisch
Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%
J. Am. Coll. Cardiol., March 6, 2002; 39(5): 780 - 787.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
D. Bansch, M. Antz, S. Boczor, M. Volkmer, J. Tebbenjohanns, K. Seidl, M. Block, F. Gietzen, J. Berger, and K. H. Kuck
Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT)
Circulation, March 26, 2002; 105(12): 1453 - 1458.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strickberger, S. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Strickberger, S. A.